The benefit of minocycline on negative symptoms of schizophrenia in patients with recent-onset psychosis (BeneMin): a randomised, double-blind, placebo-controlled trial

Lancet Psychiatry

Fecha de publicación: 12 october 2018


Autores: Prof Bill Deakin, FMedSci., John Suckling, PhD., Thomas R E Barnes, DSc., Kelly Byrne, BA., Imran B Chaudhry, MD., Paola Dazzan, PhD., et al.

Background: The antibiotic minocycline has neuroprotective and anti-inflammatory properties that could prevent or reverse progressive neuropathic changes implicated in recent-onset schizophrenia. In the BeneMin study, we aimed to replicate the benefit of minocycline on negative symptoms reported in previous pilot studies, and to understand the mechanisms involved.

Seguir leyendo

Enviar comentario